Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
NCT00716066 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53
Last updated 2026-02-27
Summary
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.
Conditions
- Autoimmune Disease
- Neurologic Autoimmune Disease
- Autologous Transplant Autoimmune
- Multiple Sclerosis Transplant
- MS Stem Cell Transplant
- Multiple Sclerosis Stem Cell Transplant
- Stiff Person Syndrome
- HCT for Neurologic Autoimmune Disorders
- CIDP Transplant
- Myasthenia Gravis Transplant
- Autoimmune Nervous System Disorder
- Central Nervous System Vasculitis
- Cerebellar Degeneration
- Chronic Inflammatory Demyelinating Polyneuropathy
- Lambert Eaton Myasthenic Syndrome
- Myasthenia Gravis
- Neuromyelitis Optica
- Opsoclonus Myoclonus Syndrome
- Rasmussen Subacute Encephalitis
Interventions
- BIOLOGICAL
-
Anti-Thymocyte Globulin
Given IV
- PROCEDURE
-
Autologous Hematopoietic Stem Cell Transplantation
Undergo autologous or syngeneic stem cell transplantation
- DRUG
-
Carmustine
Given IV
- DRUG
-
Given IV
- DRUG
-
Etoposide
Given IV
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- DRUG
-
Melphalan
Given IV
- PROCEDURE
-
Peripheral Blood Stem Cell Transplantation
Undergo autologous or syngeneic stem cell transplantation
- DRUG
-
Given PO
- PROCEDURE
-
Syngeneic Bone Marrow Transplantation
Undergo syngeneic bone marrow transplantation
Sponsors & Collaborators
-
Fred Hutchinson Cancer Center
lead OTHER
Principal Investigators
-
Leona Holmberg · Fred Hutch/University of Washington Cancer Consortium
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Max Age
- 71 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-06-30
- Primary Completion
- 2025-12-30
- Completion
- 2030-01-31
Countries
- United States
Study Locations
More Related Trials
-
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
NCT00006055 ·Status: UNKNOWN ·Phase: NA
-
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
NCT00004181 ·Status: COMPLETED ·Phase: PHASE2
-
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
NCT00238433 ·Status: COMPLETED ·Phase: PHASE2
-
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
NCT06895473 ·Status: RECRUITING ·Phase: PHASE2
-
Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders
NCT00010335 ·Status: COMPLETED ·Phase: PHASE1
-
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
NCT05993611 ·Status: SUSPENDED ·Phase: PHASE1
-
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
NCT01840566 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
NCT00278564 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
NCT00017654 ·Status: UNKNOWN ·Phase: NA
-
Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases
NCT00742300 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
NCT00899847 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
NCT00587054 ·Status: COMPLETED ·Phase: PHASE2
-
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
NCT00691015 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
NCT00006054 ·Status: TERMINATED ·Phase: NA
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
NCT01624805 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma
NCT01178645 ·Status: UNKNOWN ·Phase: PHASE2
-
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
NCT03663933 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse
NCT00002554 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
NCT00186628 ·Status: COMPLETED ·Phase: PHASE2
-
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
NCT00005988 ·Status: COMPLETED ·Phase: PHASE1
-
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
NCT01769911 ·Status: WITHDRAWN ·Phase: NA
-
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
NCT00107354 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)
NCT02529839 ·Status: UNKNOWN ·Phase: NA
-
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
NCT00017550 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplant for Immunologic or Histiocytic Disorders
NCT00176865 ·Status: COMPLETED ·Phase: PHASE2